Multimodality Cardiovascular Imaging in the Evaluation of Cardiac Sarcoidosis
JACC: Cardiovascular Imaging · 2026-10
DOI: 10.1016/j.jcmg.2026.07.024 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift JACC: Cardiovascular Imaging, 2026-10. Verfasst von Katharine E Thomas und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford Centre for Clinical Magnetic Resonance Research (OCMR), U…. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 107 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: British Heart Foundation, NIHR Oxford Biomedical Research Centre, Brigham and Women's Hospital.
Abstract (Originalsprache)
Cardiac sarcoidosis (CS) is a granulomatous disease associated with increased cardiovascular risk, including symptomatic high-grade atrioventricular block, ventricular arrhythmia, heart failure, and sudden cardiac death. Diagnosis can be challenging and requires a high index of suspicion. Although endomyocardial biopsy demonstrating noncaseating granulomas can diagnose CS with high specificity, sampling error leads to low sensitivity. CS is typically diagnosed using a combination of clinical criteria and advanced cardiac imaging, such as cardiac magnetic resonance and positron emission tomography, which can detect myocardial inflammation and fibrosis seen in CS. Recent advances in cardiac magnetic resonance and positron emission tomography have not only substantially improved the diagnosis of CS, but have also improved prognostic assessment, monitoring of treatment response, and guidance of other clinical decision-making, such as immunosuppressive and device therapy. Advanced cardiac imaging has been incorporated into recent international guidelines on inflammatory heart disease, and holds great promise to reshape contemporary clinical care for patients with CS.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford Centre for Clinical Magnetic Resonance Research (OCMR), University of Oxford, Oxford, England, United Kingdom.
- Division of Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford Centre for Clinical Magnetic Resonance Research (OCMR), University of Oxford, Oxford, England, United Kingdom; Department of Ca…
- Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.
- Department of Cardiology, Oxford University Hospitals NHS Foundation Trust, Oxford, England, United Kingdom.
- Division of Cardiovascular Medicine, Radcliffe Department of Medicine, Acute Multidisciplinary Imaging & Interventional Centre (AMIIC), University of Oxford, Oxford, England, United Kingdom.
- Division of Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford Centre for Clinical Magnetic Resonance Research (OCMR), University of Oxford, Oxford, England, United Kingdom. Electronic addre…
Förderung
- British Heart Foundation
- NIHR Oxford Biomedical Research Centre
- Brigham and Women's Hospital
Zitieren
APA
Thomas, K. E., Wicks, E. C., Divakaran, S., Sabharwal, N., Antoniades, C., Piechnik, S. K., Kwong, R. Y., & Ferreira, V. M. (2026). Multimodality Cardiovascular Imaging in the Evaluation of Cardiac Sarcoidosis. JACC: Cardiovascular Imaging. https://doi.org/10.1016/j.jcmg.2026.07.024
Vancouver
Thomas KE, Wicks EC, Divakaran S, Sabharwal N, Antoniades C, Piechnik SK, et al. Multimodality Cardiovascular Imaging in the Evaluation of Cardiac Sarcoidosis. JACC: Cardiovascular Imaging. 2026. doi:10.1016/j.jcmg.2026.07.024
BibTeX
@article{Thomas2026,
author = {Thomas, Katharine E and Wicks, Eleanor C and Divakaran, Sanjay and Sabharwal, Nikant and Antoniades, Charalambos and Piechnik, Stefan K and Kwong, Raymond Y and Ferreira, Vanessa M},
title = {Multimodality Cardiovascular Imaging in the Evaluation of Cardiac Sarcoidosis},
journal = {JACC: Cardiovascular Imaging},
year = {2026},
doi = {10.1016/j.jcmg.2026.07.024}
}
EUVIMED